IMNM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Immunome Inc (IMNM) does not present a strong buy opportunity for a beginner, long-term investor at this time. While there are positive catalysts such as strong analyst ratings and insider/hedge fund buying, the lack of recent AI or SwingMax trading signals, weak financial performance, and neutral technical indicators suggest that holding or waiting for further developments is a better option.
The MACD is negative (-0.53) and contracting, RSI is neutral at 33.53, and moving averages are converging, indicating no clear trend. The stock is trading near its support level (S1: 21.876), with resistance levels at R1: 25.994 and R2: 27.266. Overall, the technical indicators do not suggest a strong buy signal.
Analysts have consistently rated the stock as a Buy with price targets ranging from $32 to $40, citing strong Phase 3 trial results for varegacestat and its potential market dominance.
Hedge funds and insiders are significantly increasing their positions, indicating confidence in the company's future.
The stock has a 21.04% chance to increase in the next month based on historical candlestick patterns.
Financial performance is weak, with revenue dropping to zero (-100% YoY) and EPS declining by 16.67% YoY in Q3
The MACD and RSI indicators do not show bullish momentum, and the stock is trading near its support level.
Lack of recent news or congress trading data to provide additional confidence.
In Q3 2025, revenue dropped to zero (-100% YoY), net income improved slightly (-21.99% YoY), and EPS declined (-16.67% YoY). While gross margin remains at 100%, the lack of revenue and ongoing losses are concerning for long-term growth.
Analysts are highly bullish on the stock, with multiple Buy ratings and price targets ranging from $32 to $40. Positive Phase 3 trial results for varegacestat and its potential market share in a $1B-$2B market are key drivers of their optimism.
